Guru Sonpavde, MD

Experts discuss the promising future of ctDNA in bladder cancer treatment, emphasizing its potential to enhance patient outcomes and guide therapy decisions.

Experts discuss the potential of ctDNA in optimizing bladder cancer treatment, questioning overtreatment and exploring personalized therapy approaches.

Experts discuss the operational challenges and evolving use of Cignaera in cancer treatment, highlighting its potential benefits in patient care.

Explore the challenges and advancements in ctDNA-based testing for cancer care, focusing on personalized approaches and sensitivity in diverse tumor types.

Experts discuss the significance of ctDNA testing in cancer treatment, highlighting its role in patient prognosis and treatment decisions.

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

Guru P. Sonpavde, MD, discusses topline data from an exploratory analysis of CheckMate 901 in metastatic urothelial cancer.

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma. 

Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial of enfortumab vedotin plus pembrolizumab in urothelial carcinoma.

Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.

Guru P. Sonpavde, MD, discusses the methodology and key results from an analysis of the Cancer Genome Atlas in muscle-invasive bladder cancer.

Guru P. Sonpavde, MD, discusses anticipated data in bladder cancer.

Guru P. Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the potential for neoadjuvant immunotherapy in bladder cancer.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the FDA accelerated approval of erdafitinib (Balversa) in bladder cancer.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the role of durvalumab in the treatment of patients with platinum-refractory bladder cancer.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy plus chemotherapy in bladder cancer.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the next steps for the prognostic model for atezolizumab (Tecentriq) in patients with urothelial carcinoma.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses immunotherapy combination studies for the treatment of patients with urothelial carcinoma.

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a phase IIIb safety study of fixed-dose durvalumab (Imfinzi) and tremelimumab in patients with advanced urothelial carcinoma.

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses ongoing trials investigating immunotherapy for patients with penile cancer.

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.